

LIST OF CONTENTS

| | Page |
|--|----------|
| ABSTRACT | i |
| ACKNOWLEDGMENT | iii |
| LIST OF CONTENTS | iv |
| LIST OF ABBREVIATIONS | ix |
| LIST OF FIGURES | xii |
| LIST OF TABLES | xiv |
| CHAPTER ONE : INTRODUCTION | 1 |
| 1. : Human herpesviruses | 1 |
| 1.1. : EPSTEIN-BARR VIRUS (EBV) | 2 |
| 1.1.1. : Discovery and isolation of Epstein-Barr virus | 2 |
| 1.1.2. : Ultrastructure of EBV | 2 |
| 1.1.3. : Infection of EBV | 3 |
| 1.1.4. : EBV cycle in human cell | 3 |
| 1.1.5. : Primary EBV infection and seroepidemiology of the virus | 4 |
| 1.1.6. : Acute infectious mononucleosis (IM) | 5 |
| 1.1.7. : African Burkitt's lymphoma | 5 |
| 1.1.8. : Nasopharyngeal Carcinoma (NPC) | 7 |
| 1.1.9. : EBV seroepidemiological studies in Malaysia | 7 |
| 1.2. : HUMAN HERPESVIRUS 6 (HHV-6) | 8 |
| 1.2.1. : Discovery and isolation of HHV-6 | 8 |
| 1.2.2. : Ultrastructure of HHV-6 | 9 |
| 1.2.3. : Morphogenesis of HHV-6 | 10 |

| | |
|---|-----------|
| 1.2.4. : Physicochemical characteristics of HHV-6 virus replication | 10 |
| 1.2.5. : Effects of HHV-6 infection on host cell | 12 |
| 1.2.6. : HHV-6 genome | 13 |
| 1.2.7. : Variants of HHV-6 | 14 |
| 1.2.8. : Interaction between HHV-6 and other viruses | 14 |
| 1.2.9. : Primary HHV-6 infection | 16 |
| 1.2.10. : Transmission of HHV-6 | 17 |
| 1.2.11 : Persistence and latent infection of HHV-6 | 18 |
| 1.2.12. : Exanthem subitum (ES) | 19 |
| 1.2.13. : Clinical manifestation and complications of HHV-6 infection in Children | 20 |
| 1.2.14. : HHV-6 infection in adults | 21 |
| 1.2.15. : HHV-6 seroepidemiological studies in Malaysia | 21 |
| CHAPTER TWO : MATERIALS AND METHODS | 23 |
| 2.1. : Sample collection | 23 |
| 2.2. : Epstein-Barr virus indirect immunofluorescence assay | 24 |
| 2.2.1. : Cell line | 24 |
| 2.2.2. : Culture medium | 24 |
| 2.2.3. : Reviving of cells | 25 |
| 2.2.4. : Culturing of cells | 25 |
| 2.2.5. : Solutions | 25 |
| 2.2.5a. : Phosphate buffered saline (PBS) | 25 |
| 2.2.5b. : Sodium butyrate (NBA) | 26 |
| 2.2.5c. : 12-0-tetradecanoyl phorbol 13-acetate (TPA) | 26 |

| | | |
|----------------------|--|-----------|
| 2.2.6. | : Cell count and viability test | 26 |
| 2.2.7. | : Induction of P3HR-1 cells | 26 |
| 2.2.8. | : Harvesting of induced P3HR-1 | 27 |
| 2.2.9. | : IFA for EBV serosurvey | 27 |
| 2.3. | : EBV viral capsid antigen IgG ELISA test | 28 |
| 2.4. | : Human herpesvirus 6 (HHV-6) indirect immunofluorescence assay | 29 |
| 2.4.1. | : Solutions | 29 |
| 2.4.1a. | : Human interleukin-2 (IL-2) | 29 |
| 2.4.1b. | : Phytohaemagglutinin (PHA) | 29 |
| 2.4.2. | : Isolation and culture of human cord blood mononuclear cells (HCBMC) | 30 |
| 2.4.3. | : HHV-6 infection of HCBMC | 30 |
| 2.4.4. | : Harvesting of HHV-6 infected cells | 31 |
| 2.4.5. | : Confirmation of HHV-6 infection | 31 |
| 2.4.6. | : Electron microscopy | 32 |
| 2.5. | : Assessment of results | 32 |
| CHAPTER THREE | : RESULTS | 33 |
| 3.1. | : Geographical, age, sex and race distribution of persons from whom sera were obtained | 33 |
| 3.2. | : EPSTEIN-BARR VIRUS (EBV) | 36 |
| 3.2.1. | : EBV immunofluorescence assay (IFA) | 36 |
| 3.2.2a. | : Prevalence of IgG-VCA | 36 |
| 3.2.2b. | : Titres of IgG-VCA | 36 |
| 3.2.3. | : EBV seroprevalence (IgG-VCA positive) in different states | 42 |
| 3.2.4. | : EBV seroprevalence (IgG-VCA positive) in males and females | 46 |

| | | |
|--------------------------------|---|-----------|
| 3.2.5. | : Seroprevalence (IgG-VCA) of EBV in ethnic groups | 49 |
| 3.3. | : ELISA results for IgG-VCA | 52 |
| 3.4. | : Comparison of EBV seroreactivity by IFA and ELISA | 54 |
| 3.5. | : HUMAN HERPESVIRUS 6 (HHV-6) | 57 |
| 3.5.1. | : HHV-6 infection of human cord blood mononuclear cells (HCBMC) | 57 |
| 3.5.2. | : Electron microscopy of HHV-6 infected HCBMC | 57 |
| 3.5.3. | : Confirmation of HHV-6 infection in HCBMC | 57 |
| 3.5.4a. | : HHV-6 seroprevalence in different age groups | 65 |
| 3.5.4b. | : Titres of IgG anti-HHV-6 in different age groups | 65 |
| 3.5.5. | : HHV-6 seroprevalence in different regions | 68 |
| 3.5.6. | : HHV-6 seroprevalence in male and female | 72 |
| 3.5.7. | : Seroprevalence of IgG-HHV-6 by age and ethnic groups | 76 |
| 3.6. | : Serum IgG against EBV and HHV-6 | 79 |
| 3.7. | : EBV and HHV-6 seroreactivity in newborns and babies | 79 |
| CHAPTER FOUR DISCUSSION | | 83 |
| 4.1. | : EPSTEIN-BARR VIRUS | 83 |
| 4.1a. | : EBV seroconversion profile | 83 |
| 4.1b. | : EBV seroconversion patterns in different regions | 84 |
| 4.1c. | : EBV seroconversion pattern in males and females | 84 |
| 4.1d. | : EBV seroconversion pattern in different ethnic groups | 84 |
| 4.2. | : ELISA IgG-VCA | 85 |
| 4.3. | : HUMAN HERPESVIRUS 6 | 85 |
| 4.3a. | : HHV-6 seroconversion profile | 85 |

| | | |
|-------------------|---|-----|
| 4.3b. | : HHV-6 seroprevalence by age | 89 |
| 4.3c. | : HHV-6 seroprevalence in 4 regions of the country | 90 |
| 4.3d. | : HHV-6 seroconversion in males and females | 91 |
| 4.3e. | : HHV-6 seroconversion in different ethnic groups | 91 |
| 4.4. | : Comparison of EBV and HHV-6 seroconversion patterns | 92 |
| CONCLUSION | | 93 |
| REFERENCES | | 94 |
| APPENDIX | | 110 |